A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1

Key facts

Sponsor

Memorial Sloan Kettering Cancer Center

Principal Investigator

Steven Horwitz, MD

Memorial Sloan Kettering Cancer Center

Intervention

Mogamulizumab(drug)

Enrollment

134 enrolled

Eligibility

18 years · All sexes

Timeline

2024 – 2029

Study locations (7)

• Memorial Sloan Kettering at Basking Ridge (All protocol activities), Basking Ridge, New Jersey, United States
• Memorial Sloan Kettering Monmouth (All protocol activities), Middletown, New Jersey, United States
• Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States
• Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All protocol activities), Commack, New York, United States
• Memorial Sloan Kettering Westchester (All protocol activities), Harrison, New York, United States
• Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
• Memorial Sloan Kettering Nassau (All protocol activities), Uniondale, New York, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Adult T-cell leukemia/lymphoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07388563
  Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
  National Cancer Institute (NCI)
• RECRUITINGPHASE1, PHASE2NCT05745714
  HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
  Princess Maxima Center for Pediatric Oncology
• RECRUITINGPHASE2NCT07159620
  Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients
  The First Affiliated Hospital of Soochow University
• RECRUITINGPHASE1NCT07108868
  A Phase I Dose Finding Study of MB-CART2219.1
  University Hospital Tuebingen
• RECRUITINGNCT05237986
  Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
  National Cancer Institute (NCI)
• RECRUITINGPHASE1, PHASE2NCT07008885
  BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL
  Chinese PLA General Hospital
• ACTIVE NOT RECRUITINGPHASE3NCT07541755
  PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALL
  Fujian Medical University Union Hospital
• RECRUITINGPHASE2NCT06598722
  BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma.
  Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

See all trials for Adult T-cell leukemia/lymphoma →